### Phosphodiesterase 3 inhibition and cough in elderly asthmatics

**Ishiura Yoshihisa, Fujimura Masaki, Nobata Kouichi, Abo Miki, Oribe Takayoshi, Myou Shigeharu, Nakamura Hiroyuki**

**Cough**

**Volume 1**

**Number 11**

**Page range 1-6**

**Year 2005-11-24**

**URL** http://hdl.handle.net/2297/7278

**doi: 10.1186/1745-9974-1-11**
Research

Phosphodiesterase 3 inhibition and cough in elderly asthmatics

Yoshihisa Ishiura*1, Masaki Fujimura2, Kouichi Nobata2, Miki Abo1, Takayoshi Oribe1, Shigeharu Myou2 and Hiroyuki Nakamura1

Address: 1The Department of Internal Medicine, Toyama City Hospital, Toyama, Japan and 2Respiratory Medicine, Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan

Email: Yoshihisa Ishiura* - ishiura@tch.toyama.toyama.jp; Masaki Fujimura - fujimura@med3.m.kanazawa-u.ac.jp; Kouichi Nobata - nobata@med3.m.kanazawa-u.ac.jp; Miki Abo - abo@med3.m.kanazawa-u.ac.jp; Takayoshi Oribe - orib@med3.m.kanazawa-u.ac.jp; Shigeharu Myou - myou@med3.m.kanazawa-u.ac.jp; Hiroyuki Nakamura - nakamura-h@tch.toyama.toyama.jp

* Corresponding author

Abstract

Aims: Cough is a common symptom of bronchial asthma, a chronic inflammatory airway disease. Recently, the therapeutic effects of selective phosphodiesterase (PDE) inhibitors have been focused on bronchial asthma. This study was designed to investigate the clinical effect of PDE 3 inhibition on cough reflex sensitivity in elderly patients with bronchial asthma.

Methods: Effects of cilostazol, a PDE 3 inhibitor, on cough response to inhaled capsaicin were examined in 11 patients over 70 years with stable asthma in a randomized, placebo-controlled cross over study. Capsaicin cough threshold, defined as the lowest concentration of capsaicin eliciting five or more coughs, was measured as an index of airway cough reflex sensitivity.

Results: The cough threshold was significantly (p < 0.05) increased after two-week treatment with cilostazol (100 mg twice a day orally) compared with placebo [48.8 (GSEM 1.4) vs. 29.2 (GSEM 1.3) µM].

Conclusion: These findings indicate that PDE 3 inhibition may be a novel therapeutic option for elderly patients with asthma, especially for their cough symptoms.

Introduction

Chronic cough is a frequent problem in general practice and one of the commonest reasons for referral to respiratory clinic. A patient’s quality of life becomes severely affected through loss of sleep, interruption of work and social embarrassment. Every effort should be made to clarify the cause of cough because specific therapy has a higher likelihood of success than empirical therapy. A previous study revealed that patients with persistent cough had three times the risk of developing chronic wheezing as compared to normal subjects [2]. Thus, it is important to disclose the mechanism of persistent cough and to develop more efficacious treatment. Though cough has been considered to result from stimulation of airway sensory nerve endings within the respiratory tract [1], the potential mechanism by which the cough reflex may be altered in humans remains obscure.
**Table 1: Clinical characteristics of asthmatic patients**

| Patient number | Age (yr) | Sex | Height (cm) | Type | Severity | Total IgE in serum (IU/ml) | Specific IgE in serum | Complication of allergic disease | RT20-FEV1 (mg/ml) | Bronchodilator response (%) | BDP (µg/day) | Theophylline (mg/day) | Clenbuterol (µg/day) | Carbocysteine (mg/day) |
|----------------|----------|-----|-------------|------|----------|---------------------------|-----------------------|---------------------------|----------------|--------------------------|-------------|-----------------|-----------------|---------------------|
| 1              | 81       | M   | 154         | Int  | Moderate | 75                         | -                     | -                         | 2.50           | 34.0                     | 800          | 0               | 40              | 1500                |
| 2              | 72       | F   | 151         | Ext  | Moderate | 464                        | HD                    | AR                       | 2.50           | 25.4                     | 800          | 0               | 0               | 0                   |
| 3              | 80       | F   | 143         | Ext  | Moderate | 3                          | Mite, HD              | -                         | 1.25           | 27.0                     | 800          | 0               | 40              | 0                   |
| 4              | 72       | F   | 148         | Int  | Mild     | 28                         | -                     | -                         | 0.08           | 19.4                     | 0            | 0               | 40              | 0                   |
| 5              | 79       | F   | 142         | Int  | Moderate | 37                         | -                     | -                         | 5.00           | 27.6                     | 800          | 0               | 20              | 1500                |
| 6              | 72       | F   | 150         | Int  | Moderate | 57                         | -                     | -                         | 0.31           | 22.3                     | 400          | 0               | 40              | 0                   |
| 7              | 72       | F   | 147         | Ext  | Moderate | 647                        | HD, Ceder             | -                         | 0.31           | 31.8                     | 800          | 0               | 20              | 1500                |
| 8              | 70       | F   | 140         | Int  | Moderate | 17                         | -                     | -                         | 1.25           | 17.6                     | 800          | 0               | 40              | 1500                |
| 9              | 75       | M   | 162         | Ext  | Moderate | 148                        | HD, Ceder             | AR                       | 2.50           | 14.1                     | 800          | 0               | 40              | 1500                |
| 10             | 71       | M   | 165         | Ext  | Moderate | 133                        | Mite, Ceder           | AR                       | 1.25           | 14.6                     | 0            | 0               | 40              | 1500                |
| 11             | 80       | M   | 165         | Int  | Moderate | 2                          | -                     | -                         | 2.50           | 12.6                     | 400          | 0               | 0               | 0                   |

Ext, extrinsic; Int, intrinsic; HD, house dust; AR, allergic rhinitis; BDP, beclomethasone dipropionate inhalation.

*PC20-FEV1 shows concentration of inhaled methacholine causing a 20% fall in FEV1.

**Bronchodilator response means percent increase in forced expiratory volume in 1s (FEV1) from the baseline value after inhalation of 300 µg of salbutamol sulfate.

All patients used inhaled β2-agonists (salbutamol or procaterol) on demand.
Recently, considerable attention has been focused on the potential use of selective inhibitors of cyclic nucleotide phosphodiesterases (PDEs) in the treatment of respiratory diseases as PDE isoenzymes may play an important role in the regulation of airway caliber and bronchial smooth muscle function [3]. It has been shown that PDE 3 and PDE 4 are the major adenosine 3’ 5’-cyclic monophosphate (cyclic-AMP) – hydrolyzing enzymes and that human airway smooth muscle contains isozymes of the PDE families [4,5]. Furthermore, human lung tissue contains multiple PDE isozymes [6]. Therefore, it is important to determine the possible role of inhibition of these PDE isozymes in vivo. Though previous research failed to prove a bronchodilator effect of a PDE 3 and PDE 4 dual inhibitor, zardaverine, in patients with partially reversible chronic airway obstruction [7], others indicated the protective effect of selective PDE 3 and PDE 4 inhibitors [8,9]. We have demonstrated that a phosphodiesterase 3 inhibitor, cilostazol, reduces bronchial hyperresponsiveness to inhaled methacholine in elderly patients with stable asthma [10].

Based on these findings, this study was designed to elucidate the potential importance of orally administered cilostazol on cough reflex sensitivity to inhaled capsaicin in asthmatic elderly patients.

Figure 1
Individual data of capsaicin cough threshold before each treatment and after placebo and cilostazol treatments in elderly patients with stable bronchial asthma. Each horizontal bar represents geometric mean value. Closed circles and open circles represent patients undergoing steroid inhalation therapy and patients without steroid inhalation therapy, respectively. P values: Wilcoxon signed-ranks test using logarithmically transformed values.
All patients were lifetime nonsmokers or ex-smokers with no history of viral infection for at least 4 weeks prior to the study. Informed consent was obtained from all subjects. Characteristics of individual patients are shown in table 1. This study was approved by the Ethics Committee of our hospital.

Each asthmatic patient satisfied the American Thoracic Society definition of asthma, with symptoms of episodic wheezing, cough, shortness of breath responding to bronchodilators and reversible airflow obstruction documented on at least one previous pulmonary function study [11]. Reversibility was defined as greater than 12% increase in the forced expiratory volume in one second (FEV₁) following inhalation of 200 µg salbutamol sulfate. All patients had bronchial hyperresponsiveness as shown in table 1 and were taking oral (short-acting clenbuterol) and/or aerosol β₂-agonists (short-acting procaterol), inhaled steroids (beclomethasone dipropionate) and/or mucolytic agents (carbocysteine). They had not received oral theophylline or oral steroid therapy for at least eight weeks. This study was carried out when their symptoms were mild and stable.

Assessment of cough reflex sensitivity to inhaled capsaicin
Cough reflex sensitivity was assessed by a capsaicin provocation test [12]. Capsaicin (30.5 mg) was dissolved in Tween 80 (1 mL) and ethanol (1 mL) and then dissolved in physiological saline (8 mL) to make a stock solution of 1 × 10⁻² M, which was stored at -20°C. This solution was diluted with physiological saline to make solutions starting at a concentration of 0.49 µM and increased by doubling concentrations up to 1000 µM. Each subject inhaled a control solution of physiological saline followed by five or more coughs were elicited. The nebulizer output was 0.21 mL/min. The number of capsaicin-induced coughs were counted by a blindfolded medical technician in our pulmonary function laboratory. The cough threshold was defined as the lowest concentration of capsaicin that elicited five or more coughs.

Table 2: Pulmonary function on cilostazol and placebo treatments in patients with bronchial asthma

|                | Run-in      | Placebo    | Wash out   | Cilostazol |
|----------------|-------------|------------|------------|------------|
| FVC as % pred. (%) | 102.3 ± 5.7 | 104.7 ± 5.8 | 102.1 ± 5.1 | 108.4 ± 4.7 |
| FEV₁ as% pred. (%) | 98.5 ± 8.2 | 100.4 ± 7.7 | 98.5 ± 6.6 | 106.3 ± 7.3 |

Data are shown as mean value ± standard error of the mean.

Study protocol
The subjects’ concomitant medication was stopped at 9.00 p.m. on the previous day to allow a washout time of 12 h or more before the measurement of cough threshold to inhaled capsaicin at 10.00 a.m. on each test day to reduce the diurnal variability of cough response. Each patient attended 4 times, once every 2 weeks, at the same time each day. A control measurement of capsaicin cough threshold was carried out before the first treatment. After a two week wash out period, treatment with cilostazol and a placebo was performed in a randomized, crossover fashion, with a washout period of 2 weeks between treatments. Two cilostazol tablets (100 mg) or their placebo were taken orally two times a day for 14 days at 8.00 a.m. on the test day. FEV₁ was measured on a dry wedge spirometer (Transfer Test, P.K. Morgan Ltd., UK) before the capsaicin challenge to assess the bronchoactive effect of the treatment regimens.

Data analysis
Capsaicin cough threshold values were expressed as a geometric mean with a geometric standard error of the mean (GSEM). Forced vital capacity (FVC) and FEV₁ were shown as arithmetic mean values ± SEM. The cough threshold, the FVC and the FEV₁ values were compared between each pair of the four test periods (run-in, placebo treatment, wash out and cilostazol treatment) by the Wilcoxon signed-ranks test. Data was transformed to logarithmic values for cough threshold at this test. A p-value of 0.05 or less was taken as significant.

Results
Cough threshold to inhaled capsaicin before each treatment (run-in and washout period) and after treatment with cilostazol and placebo are shown in figure 1. Geometric mean values for the cough threshold were 25.9 (GSEM 1.4) µM in run-in period, 27.5 (GSEM 1.4) µM in washout period, 48.8 (GSEM 1.4) µM after cilostazol treatment and 29.2 (GSEM 1.3) µM after placebo treatment. The cough threshold after the cilostazol treatment was significantly (p < 0.05) greater than the value after the placebo treatment. FVC or FEV₁ value was not significantly different between run-in period, washout period, cilostazol treatment and placebo treatment as shown in table 2.
There were no changes in serum IgE and peripheral blood eosinophils, therefore, treatment with cilostazol did not affect the IgE production or peripheral blood eosinophil count. After the administration of cilostazol, none of the patients complained of headache. Other adverse effects such as palpitations, flushing, and dizziness were not observed with the cilostazol treatment in patients participating in this study, since the side effects of cilostazol are less frequent in elderly patients as shown in our previous study [10].

**Discussion**

The present study showed that two-week treatment with a PDE 3 inhibitor, cilostazol, increased the cough threshold inhaled capsaicin in elderly patients with stable asthma. No difference could be found in the baseline pulmonary function, peripheral blood eosinophil counts and IgE production between cilostazol and placebo treatments. From these findings, PDE 3 inhibition may be useful in elderly patients suffering from bronchial asthma, especially cough predominant asthma.

Although cough is a protective reflex that facilitates the expulsion of mucus from the airways, chronic cough causes major functional limitation in a great number of people who seek medical service. It is well known that cough can be the sole manifestation in some asthmatic patients [13], however, the precise mechanism correlating to the cough reflex in this disorder remains obscure. A recent study revealed that inflammatory mediators play major roles in the pathogenesis of bronchial asthma; however, the relationship between inflammatory mediators and airway cough reflex sensitivity also remains unclear. Previous studies showed that some inflammatory mediators can modulate the sensitivity of the cough reflex [14,15]. We indicated that intrinsic thromboxane A2 (TXA2) is a possible modulator, augmenting both airway cough reflex sensitivity and bronchial responsiveness whilst not having a bronchoconstricting effect in stable asthmatics [14,16,17]. Other studies reported that prostaglandin F2α (PGF2α) enhances airway cough reflex sensitivity with bronchoconstricting effect [18,19]. It has also been shown that inhaled prostaglandin E2 (PGE2), which acts as a bronchodilator, enhances cough reflex sensitivity [19,20]. These findings indicate the variable role of inflammatory mediators in the local control of cough reflex with no relation to bronchoconstriction.

Previous studies have shown the effects of selective inhibition of PDE isozymes in inhibition of inflammatory cell function and relaxation of airway smooth muscle in asthmatic airways [3-9,21]. Bachelet et al have shown that alveolar macrophages from asthmatic patients have increased PDE activity [22]. Other researchers have indicated that PDE 3 is closely coupled to the regulation of prostaglandin D2 (PGD2) generation [23]. Recently we demonstrated the bronchoprotective effect of PDE 3 inhibition in asthmatic patients [10,24,25], on the basis that PDE 3 is indeed present in human airway smooth muscle [26]. We, therefore, carried out this study on the assumption that PDE 3 activity in an asthmatic airway might also lead to increased sensitivity of airway cough response and concluded that a selective PDE 3 inhibitor, cilostazol, can modulate to reduce the airway cough sensitivity to inhaled capsaicin. We also showed that there was no improvement in lung function despite our previous study [10]. Though the precise mechanism for this discordant remains obscure, we stipulate that the difference in the cilostazol administration period may be a possible cause of the discordant, because in our previous study, bronchodilation was observed with a single administration of cilostazol. Precise mechanisms for the improvement of cough reflex sensitivity indicated in this study also remains unclear because we did not measure PC20. One of the possible mechanisms is that elevation of cyclic-AMP induced by PDE 3 inhibition may play some role in the regulation of cell activity and airway cough reflex sensitivity [26].

Furthermore, the bronchoprotective effect of PDE 3 inhibition for non-asthmatic subjects was not examined. There is therefore a need for further studies in patients with other bronchial disorders and normal subjects.

In conclusion, the present study clearly indicates that PDE 3 inhibition can attenuate cough reflex sensitivity in the airways of elderly asthmatic patients. Oral administration of cilostazol may be a novel therapeutic option for patients with bronchial asthma, for whom cough is an especially troublesome symptom. This is the first report demonstrating the efficacy of PDE 3 inhibition in view of cough reflex sensitivity in elderly asthmatics. Further studies are required to investigate the role of other PDE isozymes in airway cough reflex sensitivity in bronchial asthma.

**Abbreviations**

cyclic-AMP = adenosine 3’ 5’-cyclic monophosphate; CVA = cough variant asthma; FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; GSEM = geometric standard error of the mean; PDE = phosphodiesterase; PGD2 = prostaglandin D2; PGE2 = prostaglandin E2; PGF2α = prostaglandin F2α; TNF-α = tumor necrosis factor-α; TXA2 = thromboxane A2; TXB2 = thromboxane B2.

**References**

1. Irwin RS, Boulet LP, Cloutier MM, Fuller R, Gold PM, Hoffstein V, Ing AJ, McCool D, O’Byrne P, Poe RH, Prakash UBS, Pratter MR, Rubin BK. Managing cough as a defense mechanism and as a symptom. Chest 1998, 114:133S-181S.
2. Giles GG, Gibson HB, Lickis N, Shaw K: Respiratory symptoms in Tasmanian adolescents: A follow-up of the 1961 birth cohort. *Aust NZ J Med* 1994, 14:631-637.

3. Schmidt D, Dent G, Rabe KF: Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease. *Clin Exp Allergy* 1999, 29:599-5100.

4. Torphy TJ, Undem BJ, Cieslenski LB, Luttmann MA, Reeves ML, Hay DW: Identification, characterization and functional and normal role of phosphodiesterase isozymes in human airway smooth muscle. *J Pharmacol Exp Ther* 1993, 265:1213-1223.

5. Torphy TJ, Cieslenski LB: Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. *Mol Pharmacol* 1990, 37:206-214.

6. Bergstrand H, Kristoffersson J, Lundquist B, Schurmann A: Effects of antiallergic agents, compound 48/80 and some reference inhibitors on the selectivity of partially purified human lung tissue adenosine cyclic 3', 5'-monophosphate and guanosine cyclic 3', 5'-monophosphate phosphodiesterases. *Mol Pharmacol* 1977, 13:38-43.

7. Ukena D, Rentz K, Reiber C, Sybrecht GW: Effect of the mixed phosphodiesterase 3/4 inhibitor, zarzaderine, on airway function in patients with chronic airflow obstruction. *Respir Med* 1995, 89:441-444.

8. Foster RW, Rakshi K, Carpenter JR, Small RC: Trials of the bronchodilator activity of the isoenzymes-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test. *Br J Pharmacol* 1992, 34:527-534.

9. Brunnee T, Engelstatter R, Steinijans VW, Kunkekl G: Bronchodilator effect of inhaled zarzaderine, a phosphodiesterase 3 and 4 inhibitor, in patients with asthma. *Eur Respir J* 1992, 5:982-985.

10. Fujimura M, Kamio Y, Myou S, Hashimoto T, Matsuda T: Effect of a phosphodiesterase inhibitor, cilostazol, on bronchial hyperresponsiveness in elderly patients with asthma. *Int Arch Allergy Immunol* 1997, 114:379-384.

11. American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. *Am Rev Respir Dis* 1987, 136:225-244.

12. Fujimura M, Sakamoto S, Kamio Y, Myou S, Matsuda T: Effects of methacholine-induced bronchoconstriction and proacaterol-induced bronchodilation on cough receptor sensitivity to inhaled capsaicin and tartaric acid. *Thorax* 1992, 47:441-445.

13. Corrao WM, Braman SS, Irwin RS: Chronic cough as the sole presenting manifestation of bronchial asthma. *N Engl J Med* 1979, 300:633-637.

14. Fujimura M, Kamio Y, Karahara K, Bando T, Hashimoto T, Matsuda T: Prostanoids and cough response to capsaicin in asthma and chronic bronchitis. *Eur Respir J* 1995, 8:1499-1505.

15. Choudry NB, Fuller RW, Pride NB: Sensitivity of the human cough reflex: Effect of inflammatory mediators prostaglandin E2, bradykinin, and histamine. *Am Rev Respir Dis* 1989, 140:137-141.

16. Fujimura M, Sakamoto S, Saito M, Miyake Y, Matsuda T: Effect of a thromboxane A2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in asthmatic subjects. *J Allergy Clin Immunol* 1991, 87:23-27.

17. Fujimura M, Kamio Y, Hashimoto T, Matsuda T: Thromboxane A2 and sulfidopeptide leukotrienes in cough reflex in response to inhaled capsaicin in asthmatic subjects. *Jpn Soc Bronchology* 1998, 20:4-10.

18. Horton EJ: Prostaglandins and smooth muscle. *Br Med Bull* 1979, 35:295-300.

19. Storey R, Barnes PJ, Fuller RW: Contrasting effects of prostaglandins E2 and F2 on sedisitivity of the human cough reflex. *J Appl Physiol* 1992, 73:649-653.

20. Wasserman MA, Griffin RL, Marsalisi FB: Inhibition of bronchoconstriction by aerosols of prostaglandins E1 and E2. *J Pharmacol Exp Ther* 1980, 214:68-73.

21. Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW, Torphy TJ: Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. *J Pharmacol Exp Ther* 1994, 270:250-259.

22. Bachelet M, Vincent D, Havet N, Marrash-Chahla R, Pradalier A, Dry J, Vargafik BB: Reduced responsiveness of adenosine cyclase in aheeval macrophages from patients with asthma. *J Allergy Clin Immunol* 1991, 88:322-328.

23. Weston MC, Anderson N, Peachell PT: Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. *Br J Pharmacol* 1997, 121:287-295.

24. Myou S, Fujimura M, Kamio Y, Ishiura Y, Tachibana H, Hirose T, Hashimoto T, Matsuda T: Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. *Am J Respir Crit Care Med* 1999, 160:817-820.

25. Myou S, Fujimura M, Kamio Y, Hirose T, Kita T, Tachibana H, Ishiura Y, Watanabe K, Hashimoto T, Nakao S: Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminoxyline in asthmatic patients. *Br J Clin Pharmacol* 2003, 55:341-346.

26. de Boer J, Philipsen AJ, van Amsterdam RG, Shahid M, Zaagsma J, Nicholson CD: Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. *Br J Pharmacol* 1992, 106:1028-1034.